Camonsertib

DB18888InvestigationalSmall molecule

Camonsertib is under investigation in clinical trial NCT04497116 (Study of RP-3500, Camonsertib, in Advanced Solid Tumors).

Chemical structure of Camonsertib
Formula / weight
C21H26N6O3 · 410.478 g/mol (avg)
Also known as
1R,3r,5S)-3-{6-[(3R)-3-methylmorpholin-4-yl]-1-(1Hpyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol · 8-Oxabicyclo[3.2.1]octan-3-ol, 3-[6-[(3R)-3-methyl-4-morpholinyl]-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-, (3-endo)-
Code names
RP-3500

Resolves to

Compound
UNIIS1Z7Y5G56TCAS2417489-10-0ChEMBLCHEMBL5095260
Structure
InChIKeyYIHHYCIYAIVQKX-MBIULKOWSA-NSMILESC[C@@H]1COCCN1C1=CC(=C2C=NN(C3=NNC=C3)C2=N1)[C@@]1(O)C[C@@H]2CC[C@H](C1)O2
Targets
Q13535ATR

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Camonsertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In